<DOC>
	<DOCNO>NCT02850627</DOCNO>
	<brief_summary>The purpose study test expression microRNAs relate syndrome intervention Tongguan capsule , preliminarily investigate mechanism effect Tongguan capsule , provide biological foundation curative effect Tongguan capsule .</brief_summary>
	<brief_title>The Effect Tongguan Capsule MicroRNA Profiles Coronary Heart Disease Patients</brief_title>
	<detailed_description>The primary end point core whole experiment scheme . miRNAs regulate gene expression posttranscriptionally degrade messenger RNA ( mRNA ) target block translation Secondary endpoint include The adverse cardiac clinical event ( MACE ) term cardiac death , periprocedural myocardial infarction ( MI ) , spontaneous MI target vessel revascularization ( TVR ) . Related parameter qi blood material basis blood conversion objective performance use evaluate effect Tongguan capsule patient blood stagnation , either interpretation theory qi deficiency blood stagnation mutual transformation qi blood find target Tongguan capsule blood . Routine laboratory test use screen patient basic situation ensure safety experiment The traditional Chinese medicine syndrome scale Including score deficiency qi score blood stasis syndrome mainly use identify patient traditional Chinese medicine syndrome type Approximately 100 patient Coronary Heart Disease Patients Blood Stasis Syndrome undergo percutaneous coronary intervention enrol randomize divide Qi -stagnation blood stasis , Qi- deficiency blood stasis , PCI surgery , Qi deficiency blood stasis group randomly divide Tongguan capsule group control group , qi stagnation blood stasis group , , give patient Tongguan capsule 3 pill three time day ( 1.5g/day ) , every three month follow-up , follow six month</detailed_description>
	<mesh_term>Infarction</mesh_term>
	<mesh_term>Heart Diseases</mesh_term>
	<mesh_term>Myocardial Infarction</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<criteria>1 . In line diagnostic criterion acute coronary syndrome ( ACS ) , coronary angiography confirm coronary heart disease ( CHD ) , parallel Percutaneous transluminal coronary angioplasty ( PTCA ) and/or coronary stent implantation successful 2 . Postoperative routine drug treatment 3 . Traditional Chinese Medicine syndrome differentiation qi deficiency qi stagnation blood stasis blood stasis license 4 . Aged 35 75 year old 5 . Must sign consent form . 1 . Renal insufficiency , male serum creatinine &gt; 2.5 mg/dl ( &gt; 220 umo/l ) , woman &gt; 2.0 mg/dl ( &gt; 175 umo/l ) 2 . With obvious liver disease Alanine aminotransferase ( ALT ) ï¼Œ Aspartate aminotransferase ( AST ) , 3 time higher normal ceiling 3 . Serious cardiac insufficiency ( EF &lt; 35 % ) 4 . Uncontrolled patient high blood pressure 5 . Merger severe valvular heart disease acute cerebrovascular disease 6 . Random blood glucose great tendency 13.7 / L diabetes glycosylated hemoglobin 9.5 % 7 . Patients severe mental illness 8 . Patients malignant tumor life expectancy less three year 9 . Patients severe hematopoietic system disease 10 . Refused sign consent form , estimate compliance poorer , followup possibility claim ; 11 . Pregnancy ready pregnant woman , nurse mother ; 12 . Participated nearly three month , clinical subject .</criteria>
	<gender>All</gender>
	<minimum_age>35 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>acute coronary syndrome</keyword>
	<keyword>Tongguan capsule</keyword>
	<keyword>miRNAs</keyword>
</DOC>